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Bispecific antibodies (bsAbs) are of significant importance
to the development of novel antibody-based therapies, and
heavy chain (Hc) heterodimers represent a major class of
bispecific drug candidates. Current technologies for the gen-
eration of Hc heterodimers are suboptimal and often suffer
from contamination by homodimers posing purification
challenges. Here, we introduce a new technology based on
biomimicry wherein the protein-protein interfaces of two dif-
ferent immunoglobulin (Ig) constant domain pairs are
exchanged in part or fully to design new heterodimeric
domains. The method can be applied across Igs to design Fc
heterodimers and bsAbs. We investigated interfaces from
human IgACH3, IgDCH3, IgG1 CH3, IgMCH4, T-cell recep-
tor (TCR) /, and TCR / constant domain pairs, and we
found that they successfully drive human IgG1 CH3 or IgM
CH4 heterodimerization to levels similar to or above those of
reference methods. A comprehensive interface exchange
between the TCR / constant domain pair and the IgG1
CH3 homodimer was evidenced by X-ray crystallography and
used to engineer examples of bsAbs for cancer therapy.
Parental antibody pairs were rapidly reformatted into scal-
able bsAbs that were free of homodimer traces by combining
interface exchange, asymmetric Protein A binding, and the
scFv  Fab format. In summary, we successfully built several
new CH3- or CH4-based heterodimers that may prove useful
for designing new bsAb-based therapeutics, and we antici-
pate that our approach could be broadly implemented across
the Ig constant domain family. To our knowledge, CH4-based
heterodimers have not been previously reported.
Theneed to improve the clinical efficacy of antibodies has led
to an increased interest in bsAbs4 (1–4). bsAbs combine spec-
ificities of two antibodies in a single antibody construct that is
able to bind two different epitopes on the same or on different
antigens. Among the multitude of bsAb formats, the Hc het-
erodimer format is found in a majority of drug candidates as
this Fc-containing architecture intrinsically benefits from a
long serum half-life and the ability to mediate effector func-
tions (5). It allows the design of asymmetric bsAbs wherein
two different antigen-binding arms are, respectively, part of
two different Hc chains that heterodimerize instead of form-
ing homodimers, usually through a pair of engineered CH3
domains.
Hc heterodimerization (HD) was first reported by Atwell et
al. (6) using a technique known as “knobs-into-holes” (KiH).
The technology is based on an engineered pair of CH3 domains
that heterodimerizes (CH3 heterodimer) and involves intro-
ducing mutations that create a protuberance in the interface of
the first CH3 domain and a corresponding cavity in the inter-
face of the secondCH3 domain, such that the protuberance can
be positioned in the cavity to promote heterodimer assembly
and hinder homodimer formation. Developed in the mid-
1990s, large scale expression and production of KiH-based
bsAbs inmammalian cells have been reported to be challenging
due to variable heterodimer purity (7). Furthermore, KiH was
initially hampered due to the random light chain (Lc) associa-
tion inherent to themethod.Originally, the use of a commonLc
derived from phage display screens was proposed but never
broadly reported (8, 9). A more recent solution involves a
domain crossover between heavy and light constant domains
within one of the Fab arms of the bsAb, thereby enforcing cor-
rect Lc pairing (10).
Over the last 6 years, several solutions to create CH3 het-
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from rational design (11–13). An example of a more systematic
approach to designHc heterodimers is found in the SEED tech-
nology (14). SEED is based on an exchange of -strands and
loops between IgA and IgG1 CH3 homodimers to create a new
CH3 heterodimer. Although the technology allows efficient
generation of Hc heterodimers, one drawback is that the result-
ing CH3 heterodimer includes 50 amino acid changes and
six amino acid insertions thereby increasing the risk of
immunogenicity.
Teachings from the current Hc HD technologies helped us
identify three key bottlenecks as follows: (i) CH3 heterodimers
that do not heterodimerize efficiently upon co-expression in
mammalian cells and yield low bispecific content, a bottleneck
that has motivated the development of Hc heterodimers in
Escherichia coli (7); (ii) contamination by homodimers occur-
ring upon scale-up (12); and (iii) Lc mispairing, an issue that is
usually addressed with a common Lc isolated from hybridoma
screens (12, 15) or a case-by-case re-engineering of the two
parental Fabs (16). To address the present shortcomings, we
first set out to design an efficient Hc HD technology; we then
implemented a platform purification solution to remove any
homodimer traces that may occur at scale-up, and finally we
used an scFv Fab format for the two binding arms to success-
fully address Lc mispairing. Importantly, the resulting bsAb is
the secretion product of onemammalian cell line thusminimiz-
ing costs and effort.
We started our engineering work by looking at 3D structures
of Ig domain pairs found in various proteins of the immune
system. Ig constant domains found in antibodies share the same
tertiary fold but also assemble into very similar quaternary
structures. TCRs are striking examples of these similarities
extending outside the antibody family with their 3D structures
being almost equivalent to the Fab portion of an antibody. As
the Ig constant domain fold is strongly conserved, we saw in
quaternary structures of antibodies and TCRs a source of pro-
tein-protein interfaces that could be used entirely or partially to
engineer new heterodimers. By exchanging residues from the
IgG1 CH3 homodimer interface with residues from the TCR
/ constant domain (TCR Ca-Cb) interface (Fig. 1A), we cre-
ated a new CH3 heterodimer that heterodimerizes more effi-
ciently than the previously described KiH and SEED technolo-
gies. Following this initial work, we succeeded in engineering
additional heterodimers based on the TCR / constant
domain (TCR Cg-Cd) interface or by exchanging half-inter-
faces between two Ig homodimers (Fig. 1B). In total, we report
the successful design of five new CH3 heterodimers and two
new CH4 heterodimers along with methods to systematically
exchange interfaces between Ig constant domain pairs using
the IMGT numbering system (17, 18). To further validate our
concept of interface exchange, we solved the crystal structure of
our initial CH3 heterodimer and demonstrated the successful
importation of the TCR Ca-Cb interface within the IgG1 CH3
domain pair.
As a proof-of-concept for the design of future therapeutic
bsAbs, we used our TCR-based HD technology or BEAT plat-
form (Bispecific Engagement by Antibodies based on the T-cell
receptor) to engineer and produce examples of bsAbs or BEATs
that target growth factor receptors broadly involved in
oncology.
Results
Hc HD technology based on an interface exchange between
TCR and antibody Ig constant domains
The IMGT database was used to identify the protein-protein
interface residues located in the -strands of various human
Ig constant domain pairs found in antibodies and TCRs
(http://www.imgt.org/IMGTrepertoire/Proteins/; section: C-
DOMAIN).5 The IMGT numbering system for C-DOMAIN
provides a link between the 3D structures of Ig constant
domains and their amino acid sequences, thus allowing the
identification of equivalent 3D positions between domains. For
all homo- and heterodimers from C-DOMAIN, we identified
the following positions as interface residues: 3, 5, 7, 20, 22, 26,
27, 79, 81, 84, 84.2, 85.1, 86, 88, and 90.
We first attempted to exchange the IgG1 CH3 homodimer
interface with the TCR Ca-Cb interface (Fig. 1A). From the
5 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Figure 1. New heterodimeric interfaces can be built in two different ways. A, using heterodimers as donor interfaces, BEAT: a heterodimeric interface, in
this case that of TCR Ca-Cb, is grafted onto a homodimeric interface such as that of IgG1 CH3. B,mixing homodimer interfaces, half of a homodimeric interface,
in this case that of IgD CH3, is grafted onto another homodimeric interface such as that of IgG1 CH3.
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analysis of the TCR Ca-Cb interface (Fig. 2), we identified four
groups of residues that could possibly disrupt theCH3 interface
symmetry and recreate some TCR contacts upon grafting (two
pairs of reciprocal sets). The first group is composed of Trp 88
in TCRCawith positions Ala 85.1 and Ser 86 in TCRCb. These
positions were selected to recreate the Trp 88 (TCR Ca)/
Ala 85.1 (TCR Cb) hydrophobic interaction and disrupt the
Tyr 86 symmetric hydrophobic contact found in IgG1 CH3.
Note that position 85.1 in the natural TCR Cb sequence corre-
sponds to a cysteine, but we used alanine to prevent disulfide
bond mispairing. The second set of residues includes position
Arg 88 inTCRCbwith positions Ser 85.1 andVal 86 inTCRCa.
Arg 88 was considered to be a silent change that will maintain
the original network of electrostatic contacts at Lys 88 in IgG1
CH3.We postulated that the introduction of Trp 88 from TCR
Ca in the other CH3 monomer would have disrupted the sym-
metric network of electrostatic contacts found on the opposite
side of the interface; thus, maintaining this network of contacts
creates asymmetry. The other substitutions were selected to
disrupt the Tyr 86 symmetric hydrophobic contact mentioned
above (Val 86) and to recreate the Val 86 (TCR Ca)/Val 22
(TCR Cb) hydrophobic contact with the help of supporting
position Val 22 in TCR Cb. Position Ser 85.1 was selected for
grafting to spatially accommodate the import of the other two
positions. The third group of residues is composed of position
Lys 20 in TCR Ca with position Thr 26 in TCR Cb. Lys 20 in
TCR Ca was imported to putatively create a new electrostatic
contact with supporting position Glu 84.2, although this inter-
action was only seen in one of the TCR Ca-Cb structures we
used for analysis (PDB code 1KGC), and Thr 26 in TCR Cb was
selected to disrupt the Lys 26/Glu 13 symmetric electrostatic
contact found in IgG1 CH3. Finally, the fourth set consists of
position Thr 20 in TCR Cb with position Thr 26 in TCR Ca.
Thr 26 in TCR Ca was selected to disrupt the Lys 26/Glu 13
symmetric electrostatic contact discussed above but found on
the opposite side of the IgG1 CH3 interface; Thr 20 in TCR Cb
was a conservative change as position 20 is a serine in IgG1
CH3. These four sets of residues are supported by other TCR
Ca-Cb interface positions; in both domains positions 3, 5, 7, 22,
79, 81, 84, 84.2, and 90 brought asymmetric contacts and/or
helped to spatially accommodate other substitutions that were
selected for exchange.
We then derived a new pair of IgG1 CH3 domains having
TCR Ca-Cb-based substitutions as follows (BEAT; Fig. 2 and
supplemental Fig. S1): a first CH3 domain based on TCR Ca
having substitutions S20K, T22V, K26T, K79Y, F85.1S, Y86V,
Figure2. Schematic diagramsdepicting the interfacesof IgG1CH3, TCR constantdomainpairs, andBEATCH3 interfaces. The interdomain interactions
were calculated from solved structures ormodels. The IMGT numbering is used. Charged residues are colored in red (negative) or blue (positive). Hydrophobic
interactions are in gray lines, and electrostatic interactions in dashed red lines. Grafted residue numbers are in yellow. The four key sets of residues selected for
grafting the TCR Ca-Cb interface onto the IgG1 CH3 homodimer are circled in dashed black lines.
Interface exchange for bispecific antibody generation
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K88W, and T90N (BEAT CH3 (A)), and a second CH3 domain
based on TCR Cb having substitutions Q3E, Y5A, L7F, S20T,
T22V, K26T, T81D, V84L, D84.2E, F85.1A, Y86S, K88R, and
T90R (BEAT CH3 (B)).
The resulting CH3 heterodimer was then used to create an
Fc-like proteinmade of twoFc-like chains, each chain including
one of the two engineered CH3 domains (Fc-like chain as fol-
lows: IgG1 hinge-IgG1 CH2-engineered IgG1 CH3 domain).
Homo- and heterodimeric Fc-like proteins are difficult to iden-
tify as these have a similar molecular weight; thus a variable Lc
 domain antibody (VL-dAb) was N-terminally fused to one of
the Fc-like chains to generate a significant difference in molec-
ular weight. The two Fc-like chains were transfected at a 1:1
ratio into HEK293-EBNA cells. Post-Protein A purification,
heterodimer formation was assessed by non-reduced SDS-
PAGE and quantified by scanning densitometry of the gel
bands.
Fig. 3A shows the results of this initial TCR Ca-Cb interface
graft versus other knownHcHD technologies. From the control
IgG1 Fc (Fig. 3A, lane 1), we observed three bands that corre-
spond to the three expected species upon randompairing of the
chains: assembled heterodimer (VL-Fc/Fc, 62.7 kDa, 46%) and
the twohomodimers (VL-Fc/VL-Fc andFc/Fc, 74.4 and 51 kDa,
respectively). Our initial TCRCa-Cb interface graft favoredHD
(Fig. 3A, lane 2, 83%) andwas later redesignedwith significantly
fewer substitutions (BEATmin; supplemental Figs. S1 and S2):
BEAT min CH3 (A) having substitutions S20K, T22V, K26T,
K79Y, K88W, and T90N and BEAT min CH3 (B) having sub-
stitutions F85.1A and Y86S and exhibiting a small increase in
HD with respect to our original graft (Fig. 3A, lane 3, 87%).
Addition of Q3A in BEAT CH3 (A) (Fig. 3A, lane 4) or removal
of T90R in BEATCH3 (B) (Fig. 3A, lane 5) allowedHD to reach
over 90% and close to 95%, respectively; this means that
homodimers were not visually detectable. The HD levels
observed for the SEED (Fig. 3A, lane 6) (14) and KiH (Fig. 3A,
lane 7) (6, 9) technologies were significantly lower, 83 and 67%,
respectively.
Another example of a natural heterodimeric interface is
found in the TCR Cg-Cd domain pair. Using the same design
approach, we grafted the TCR Cg-Cd interface onto the IgG1
CH3 homodimer (BEAT G/D), including the four key sets of
positions described above alongwith the same supporting posi-
tions (Fig. 2 and supplemental Fig. S1). The TCR Cg-Cd differs
from the TCR Ca-Cb as position 88 in both domains brings
interdomain hydrophobic interactions; in addition, two asym-
metric electrostatic contacts are present. Despite the large
number of expected asymmetric contacts, grafting the TCR
Cg-Cd interface only increased HD by 3% with respect to our
BEAT interface (BEAT G/D; Fig. 3B, lane 2, 86%).
Next, we attempted to graft the TCR Ca-Cb interface onto
another class of Ig dimer and selected the IgM CH4
homodimer. Using the same method and sets of positions, we
built a CH4 heterodimer based on the TCR Ca-Cb interface
(supplemental Figs. S1 and S2). For better comparability
between CH3 and CH4 engineering, CH4 heterodimers were
also tested in the context of an Fc-like protein wherein engi-
neered CH3 domains were replaced by engineered CH4
domains. Because CH4 domains lack Protein A binding, substi-
tutionsR115HandV116Y (IMGTnumbering)were introduced
to confer binding (pA). The CH4 heterodimer (BEATCH4 pA)
exhibited a HD rate similar to that of the BEAT CH3 het-
erodimer (Fig. 3C, lane 2, 82%).
Figure 3. SDS-PAGE analysis of the new CH3 and CH4 heterodimers based on the TCR constant domain interfaces. Engineered Fc-like proteins were
transiently expressed, purified by Protein A chromatography and analyzed by SDS-PAGE. A, BEAT Fc and variants thereof, an Fc-like protein with a CH3
heterodimer based on the TCR Ca-Cb interface; a control and Fc-like proteins based on previously described technologies are shown. B, BEAT Fc versus BEAT
G/D Fc, an Fc-like protein with a CH3 heterodimer based on the TCR Cg-Cd interface. C, BEAT CH4 Fc, an Fc-like protein with a CH4 heterodimer based on the
TCRCa-Cb interfacewherein Protein A bindingwas engineered bymutagenesis. The Fc-like protein IgMCH4pA corresponds to a control Fc-like protein based
on the IgM CH4 homodimer wherein Protein A binding was also engineered. D, summary of heterodimer content.
Interface exchange for bispecific antibody generation
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BEAT Fc characterization and crystal structure
The heterodimeric Fc derived from the original BEAT inter-
face had good transient expression and good thermal stability;
the thermal stability of the BEAT Fc region was similar to that
of the human IgG4 Fc region (19) as judged by its calorimetric
profile showing a single transition with a Tm of 70 °C (supple-
mental Fig. S3A), a melting point that is consistent with other
previously reported CH3 heterodimers such as KiH (6).
To further characterize this fragment, the BEATFcwas crys-
tallized and its 3D structure solved at high resolution (Table 1).
The same so-called “horseshoe” structure as that seen in any
natural IgG antibody was observed (Fig. 4A), with little devia-
tion from other experimentally solved structures (root mean
square deviation of 0.66Å versusPDBcode 2WAHwhen super-
imposing the CH3 domains on their C traces). Analysis of the
engineered CH3 domains revealed the successful importation
of key heterodimeric contacts found in the TCR Ca-Cb crystal
structure (Fig. 4, B and C) with 85% of the imported TCR resi-
dues maintaining their original side chain orientation in the
BEAT Fc structure. The four key sets of substitutions used in
our engineering strategy were found to have the expected func-
tions we described above (Fig. 2) and can be summarized as
follows: the first set of grafted residues recreated a pair of TCR
Ca-Cb hydrophobic contacts on one side of the interface
(Trp 88 in (A) with Ala 85.1 and Leu 24 in (B)), whereas the
second set maintained the existing network of electrostatic
interactions at the opposite side thereby creating asymmetry.
The third and fourth sets removed the Lys 26/Glu 13 pair of
symmetric electrostatic contacts. Supporting positions 3, 7, 22,
79, 84, and 90 further contributed to break symmetry and add
asymmetric contacts.Q3E in (B) created a new ionic interaction
with Lys 16 in (A). L7F in (B) removed the symmetric hydro-
phobic interaction found at this position in IgG1 CH3. V84L in
(B) created a new asymmetric hydrophobic contact with K79Y
in (A), a contact directly imported from the TCR Ca-Cb inter-
face. T22V in (B) with Leu 24 in (A) and T22V in (A) with
Leu 24 in (B) created a pair of symmetric hydrophobic contacts
that did not exist in the parental interfaces. Finally, T90R in (B)
created a new ionic interaction with Asp 84.4 in (A), another
contact that did not exist in the parental interfaces.
Addition of Q3A in (A) or back mutating position 90 (R90T)
in (B) enhanced HD. In light of the solved structure, we made
the following observations. The substitution of Gln 3 by an ala-
nine increases HD by putatively lowering steric hindrance due
to the larger side chain of the glutamine residue. In a modeled
homodimer of two BEAT CH3 (B) domains (data not shown),
we observed Arg 90 in one domain making electrostatic inter-
actions with Glu 84.2 and Asp 84.4 in the other domain (also
true for the reciprocal set of residues). By backmutating Arg 90
for threonine, these interactions are removed thereby destabi-
lizing the BEAT CH3 (B) homodimer; a similar result was
obtained by substituting Asp 84.4 for a glutamine (D84.4Q).
Although the original TCR Ca-Cb graft and variants thereof
introduce a significant number of substitutions, it is important
to note that most substitutions are buried at the heterodimer
interface with only a small number of these residues protruding
and therefore solvent-exposed, some of which are found at the
bottom of surface cavities (supplemental Fig. S3B), suggesting a
low immunogenicity risk.
Design of new heterodimers bymixing homodimeric
interfaces
The initial success of ourTCR interface exchangemethod led
to further investigations into designing new heterodimers from
two existing homodimers (Fig. 1B). Exchanging half of an
acceptor homodimer interface with the equivalent half-inter-
face of a donor homodimer was thought to be sufficient for
breaking symmetry and generating a new heterodimer. To this
end, the IgG1 CH3 interface (Fig. 2) was grafted with half of the
interface of either human IgA CH3, IgD CH3, or IgM CH4
(supplemental Fig. S2 and S4), whereas the IgM CH4 interface
was grafted with half of the interface of IgG1 CH3.
Because of the inherent symmetry found in homodimeric
interfaces, the four key sets of interface positions identified in
heterodimers only translate into two sets. Hence, one of the two
acceptor domains is designed with substitutions at positions 88
and 20with supporting substitutions at positions 79, 81, and 90,
whereas the other domain is substituted at positions 26, 85.1,
and 86 with supporting substitutions at positions 3, 5, 84, and
84.2. New heterodimers based on mixed homodimeric inter-
faces are referred to as mixed interface (MI) heterodimers (Fig.
5 and supplemental Fig. S1). Using the methods described
above, Fc-like proteins with mixed interface CH3 or CH4 het-
erodimers were built and tested as previously shown for our
TCR grafts (Fig. 6).
Our mixed IgD/IgG1 CH3 heterodimer (MI (CH3) DG/GD)
had the highest HD rate of theMI grafts, reaching 91% (Fig. 6A,
lane 3). MI CH3 heterodimers based on IgA and IgM had HD
rates above KiH but lower than SEED (Fig. 6A, lanes 4 and 5),
whereas theMI CH4 heterodimer (MI (CH4) GM/MGpA) was
Table 1
Data collection and refinement statistics of the solved BEAT Fc crystal
structure.
BEAT Fc
Data collection
Wavelength (Å) 0.9795
Space group P212121
Cell dimensions
a, b, c (Å) 49.8, 73.7, 141.5
, ,  (°) 90.0, 90.0, 90.0
Resolution (Å)a 30.00–1.97 (2.08–1.97)
Rmerge (%) 0.119 (0.765)
Rmeas (%) 0.138 (0.897)
Rpim (%) 0.069 0.458)
I/I 5.2 (1.3)
Completeness (%) 99.2 (98.6)
Redundancy 3.6 (3.5)
Refinement
Resolution (Å) 30.00–1.97 (2.02–1.97)
No. of reflections 35360/2533
Rwork/Rfree 0.210/0.279
No. atoms
Protein 3107
Sugar 220
Water 493
B factors
Protein 54.4
Sugar 96.4
Water 59.0
Root mean square deviations
Bond lengths (Å) 0.010
Bond angles (°) 1.694
a Values in parentheses are for highest-resolution shell.
Interface exchange for bispecific antibody generation
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identical to KiH (Fig. 6B, lane 2) but had a lower rate compared
with BEAT CH4 pA. The SEED technology (14) is an HD tech-
nology wherein several -strands and loops are exchanged
between IgG1 CH3 and IgA CH3 to create a new CH3 het-
erodimer. As Trp 81 mediated few hydrophobic interactions
within IgA CH3 as well as in our homology models of SEED
(supplemental Fig. S4) and MI (CH3) AG/GA (Fig. 5), we back
mutated this position for threonine to probe any differences
between the two interfaces. HD assays with the back-mutated
heterodimers showed that this position was important in SEED
but had little impact on the MI (CH3) AG/GA heterodimer
(supplemental Fig. S5, 20% versus 4% loss in HD rate, respec-
tively), demonstrating that the two methods bring a different
network of interactions. Our models did not show any differ-
ences between SEED and MI (CH3) AG/GA regarding the
hydrophobic interactions mediated by Trp 81, but the involve-
ment of core residues and/or additional interactions found in
SEED outside of the IMGT positions used in our method can-
not be excluded. In contrast, the model of our heterodimer
showed three electrostatic contacts that were not found in the
SEED model (Glu 13 (AG)/Arg 26 (GA), Lys 16 (AG)/Glu 3
(GA), and Arg 90 (AG)/Asp 84.4 (GA)).
Rapid and scalable reformatting of antibody pairs into bsAbs
bsAbs were engineered using our original BEAT interface as
this interface was well characterized at the time this work was
performed. Lc mispairing was addressed by having two differ-
ent antigen binding formats on eachHc: an scFv on one Hc and
a Fab on the other Hc (scFv  Fab). To produce bsAbs free of
homodimers, BEATantibodieswere further engineered to have
asymmetric Protein A binding. A difference in Protein A bind-
ing between the two Fc chains was created by having one Fc
chain originating from human IgG3, a natural IgG isotype that
does not bind Protein A (Fig. 7A).
In this study, dual targeting BEAT antibodies against the
clinically relevant targets EGFR (epidermal growth factor
receptor), HER2 (human epidermal growth factor receptor 2),
and HER3 (human epidermal growth factor receptor 3) were
prepared. Marketed antibodies against EGFR (Erbitux, Bristol-
Myers Squibb,MerckKGaA, and Lilly) (20) andHER2 (Hercep-
tin, Roche-Genentech) (21) were used as a source of variable
domains. Our anti-HER3 variable domains were obtained from
an anti-HER3 antibody in preclinical development (antibody
U1-59) (22). Two target combinations were prepared and
scaled-up: BEAT 1/3 (Erbitux (scFv)  anti-HER3 (Fab)) and
BEAT 2/3 (Herceptin (scFv)  anti-HER3 (Fab)). The bsAbs
were transiently expressed in HEK293-EBNA cells with yields
between 10 and 25mg/liter. HD levels in the scFv Fab format
were lower than those observed earlier with the monovalent
dAb format (74%; Fig. 7, B and C). Homodimer contaminants
were efficiently removed using Protein A chromatography
based on two isocratic elution steps. Retrospectively, it was
found that adding the D84.4Q substitution in chain (B) greatly
improved HD of BEAT antibodies (96%; Fig. 7,D and E). BEAT
antibodies exhibited good DSC and SEC profiles; for example,
BEAT 2/3 displayed a thermogram with no transition below
69 °C, and introducing the D84.4Q substitution had no impact
Figure4. Crystal structureof theBEATFc.A, ribbondiagram.B, structural alignmentof grafted residues from theBEAT interfacewith corresponding residues
in TCR Ca-Cb (IMGT numbering). The structure of the BEAT CH3 heterodimer was superimposed on that of the TCR Ca-Cb heterodimer. For BEAT, only grafted
residues are displayed at top of the TCR Ca-Cb structure (PDB code 1KGC). C, close-up showing the conservation of the side-chain orientation for positions 22
and 88 in monomer (A) and 22, 85.1, and 86 in monomer (B) between the BEAT and TCR interfaces. BEAT CH3 (A) residues are colored blue and BEAT CH3 (B)
residues are colored red.
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on its thermal stability (Fig. 8A). Additionally, the bsAb showed
a single monomeric peak by SEC (Fig. 8B). BEAT 2/3 affinities
for Fc receptors were comparable with that of Herceptin
(IgG1) (supplemental Table S1). Improvements in affinities for
FcR2a, FcR2b, and FcR3a were observed for a BEAT 2/3
variant that included both aCH2 and aCH3 from IgG3 in one of
its Fc chains. The D84.4Q substitution in BEAT 2/3 reduced
affinities for FcR1a, FcR2a, and FcR2b by 2-fold, whereas
FcR3a affinity was reduced by 25%, although still in the range
of previously reported values for other IgG1 antibodies (23).
Human IgG3 immunoglobulins are known to have a shorter
circulating half-life (24); however, using the IgG3 isotype in one
of the two Fc chains (CH2-CH3 or CH3 from IgG3) had no
impact in terms of FcRn binding, and measured affinities were
in-line with reported values (supplemental Table S1) (25).
Pharmacokinetics studies in rats showed that BEAT antibodies
benefited froma prolonged half-life similar to that of previously
reported Hc heterodimers (26, 27); for example, an elimination
half-life (t1⁄2) of 164 h following i.v. injection of 10 mg/kg of
BEAT 2/3was observed (supplemental Table S2; note that anti-
body U1-59 has been reported to cross-react with rat HER3
(22)).
BEAT antibodies retained the respective binding affinities of
their parental antibodies (20–22); for example, BEAT 2/3 was
able to co-engage its targets (Fig. 8, C and D) with affinities of
about 2–3 nM (supplemental Table S3). BEAT 1/3 and 2/3
induced antibody-dependent cellular cytotoxicity against A431
and SKBR3 cells with similar levels as that seen with Erbitux
Figure 5. Schematic diagrams depicting the interfaces of the new CH3 and CH4 heterodimers based on a mix of homodimeric interfaces. The IMGT
numbering is used. Naming convention: the domain type is stated in parentheses (CH3 or CH4) followed by the abbreviation of the engineered domain
whereinposition88was exchangedand then theabbreviationof theengineereddomainwhereinpositions 85.1 and86were exchanged. Engineereddomains
are denoted by a two-letter abbreviation as follows: the 1st letter corresponds to the Ig class of position 88, and the 2nd letter corresponds to the Ig class of
positions 85.1 and 86. Charged residues are colored in red (negative) or blue (positive). Hydrophobic interactions are shown as gray lines, and electrostatic
interactions are shown as dashed red lines. Grafted residue numbers are in yellow.
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and Herceptin, respectively (data not shown). Both bsAbs were
further tested at inhibiting the proliferation of different cancer
cell lines (Fig. 9,A–C). Duligotuzumab, a bsAb directed against
EGFR and HER3, which is currently in phase Ib for first-line
treatment of recurrent/metastatic squamous cell carcinoma of
the head and neck (28, 29), was used as a control. BEAT 1/3 and
2/3 were better at inhibiting BxPC3 (Fig. 9A) and Calu-3 cell
proliferation (Fig. 9,B andC) overmonotherapies, combination
of parental antibodies, and duligotuzumab, respectively.
HER2/HER3 targeting antibodies may constitute a promis-
ing therapeutic strategy in cancer (30); hence, we decided to
assess the in vivo antitumor efficacy of BEAT 2/3 in tumor
xenograft experiments. Naive SCID beige mice were xeno-
grafted subcutaneously with the Calu-3 cell line and treated
with BEAT 2/3, duligotuzumab, Herceptin, anti-HER3 anti-
body, and the combination therapy of Herceptin and anti-
HER3 antibody. The mean of Calu-3 tumor growth at day 40
after xenograft was used to assess antitumor efficacy (Fig. 9D
and supplemental Table S4). Although the combination ther-
apy was the most efficacious treatment, BEAT 2/3 was as effi-
cacious if not better than duligotuzumab in this model.
Discussion
We aimed to design a complete Hc HD platform that would
address the current bottlenecks and integrate into the standard
manufacturing processes used for marketed monoclonal anti-
bodies. To minimize misassembled Hc contaminants, we set
out to establish a new HD technique that is more efficient than
some of the previously described methods (6, 14). We engi-
neered a technology based on biomimicrywherein the interface
of a hetero- or a homodimer is grafted onto a recipient
homodimer to create a newheterodimer. Natural heterodimers
provide a complete interface (Fig. 1A), whereas only half-inter-
faces from homodimers are grafted to generate a new heterodi-
meric interface from two homodimeric ones (Fig. 1B). A suc-
cessful exchange is based on the concept of substituting a
residue in a recipient homodimer interface with the residue
from a donor homo- or heterodimer interface that is found at
the equivalent 3D position. Conveniently, 3D equivalent posi-
tions among Ig constant domain pairs are readily identified
via the IMGT numbering system (17, 18) thereby providing a
solution in terms of the amino acid choice that is available to
create a new heterodimeric interface. Other HD technologies
(6, 9, 11–14) do not provide for such a generic solution but
rather a case-by-case approachwherein every new heterodimer
is designed de novo without prior knowledge of the choice of
substituting residues. Another important aspect was the intrin-
sic propensity of the two domains to readily heterodimerize, as
many technologies often rely on an optimization of the ratio of
the two Fc chains to increase HD levels in transient transfec-
tions (9, 13). Hence, we monitored the assembly of our het-
erodimer candidates in transient transfections using equal
quantities of each engineered chain.
As a starting point, we designed Fc heterodimers based on
engineered IgG1 CH3 or IgM CH4 domain pairs wherein HD
was driven by an interface exchange of the homodimer protein-
protein interface with either a complete heterodimeric inter-
face (TCR Ca-Cb and TCR Cg-Cd) or half of a homodimeric
interface (IgACH3, IgDCH3, IgG1CH3, and IgMCH4). These
Fc-like proteinswere fused to a single dAb (monovalent format)
and transiently transfected at a 1:1 chain ratio.
Grafting the TCR Ca-Cb interface to engineer a new CH3
heterodimer (Fig. 2) was one of the most successful strategies,
which after some optimization of the initial graft led to a near
95% in HD, well above the levels observed for the KiH (6) and
SEED (14) technologies (Fig. 3). Upon solving the crystal struc-
ture of this initial graft, we observed the successful importation
of key TCR contacts (Fig. 4) as well as the formation of new
interactions not found in the parental interfaces.
Exchanging half-interfaces between homodimers (Fig. 5) was
also successful at driving HD (Fig. 6). Interface exchange
Figure 6. SDS-PAGE analysis of the new CH3 and CH4 heterodimers based on a mix of homodimeric interfaces. Engineered Fc-like proteins were
transiently expressed, purified by Protein A chromatography, and analyzed by SDS-PAGE. A, BEAT Fc and BEAT G/D Fc versus Fc-like proteins with a CH3
heterodimer based on half-donor interfaces from IgA CH3, IgD CH3, or IgMCH4 grafted onto the IgG1 CH3 domain pair: MI (CH3) AG/GA,MI (CH3) DG/GD, and
MI (CH3)MG/GM, respectively; the Fc-like protein based on the SEED technology is shown. B,MI (CH4) GM/MGpA corresponds to an Fc-like proteinwith a CH4
heterodimer based on grafting half of the IgG1 CH3 interface onto the IgM CH4 domain pair; the engineered CH4 heterodimer was also engineered to bind
Protein A. The Fc-like protein IgM CH4 pA is used as a control. C, summary of heterodimer content.
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Figure 7. Differential ProteinA chromatographyof BEAT antibodies.A, schematics of asymmetric Protein A binding strategy for platform removal of trace
amounts of homodimers. Upon transient transfection, the scFv Fab BEAT antibody is assembled from three different chains (middle species); traces of two
homodimeric contaminants can also be formed (top and bottom species) but are easily purified by Protein A chromatography; the Ig-like contaminant (top
species) does not bind Protein A, whereas the scFv-Fc dimer contaminant (bottom species) binds more strongly than the bispecific antibody thereby allowing
separation. A(0) means no Protein A-binding site; A() means one Protein A-binding site; and A(2) means two Protein A-binding sites. B and C, BEAT 2/3. B,
Protein A purification chromatogram. C, SDS-PAGE analysis of main peak fractions. D and E, BEAT 2/3 variant with the D84.4Q substitution. D, Protein A
purification chromatogram. E, SDS-PAGE analysis ofmain peak fractions. Gels include a control lane (Load) corresponding to culture supernatant after Protein
G purification that shows the hetero-to-homodimer ratio before loading on the Protein A column.
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between IgG1CH3 and IgDCH3was themost successful of our
half-interface grafts suggesting that exchanging half-interfaces
between Ig homodimers can be as successful as SEED when
considering the added benefit of introducing fewer substitu-
tions with no insertions (supplemental Fig. S1). Interestingly,
the majority of the MI heterodimers had a lower HD rate than
BEATs suggesting that heterodimeric interface exchange is
more efficient probably due to the fact that natural het-
erodimers provide a complete interface, which has been evo-
lutionarily selected as heterodimeric.
Nonetheless, our method could be broadly implemented
across the antibody Ig constant domain family, and we success-
fully built seven examples of new CH3 or CH4 heterodimers
with six new heterodimers exhibiting HD levels above KiH. To
our knowledge, CH4 heterodimers have not been previously
reported and may prove useful in the design of new antibody
therapeutics.
In the second part of our study, we selected our BEAT Fc
heterodimer (original TCR Ca-Cb graft) to design bsAbs based
on a good HD rate and the expression, stability, and putative
low immunogenicity profile (supplemental Fig. S3). Regardless
of theHD level achieved, we and others (7, 12, 31) found thatHc
heterodimers do contain at least trace amounts of homodimer
contaminants following scale-up, and we therefore decided to
engineer our heterodimeric Fc for asymmetric Protein A bind-
ing by using a human IgG3CH3 domain in one of the Fc chains,
thereby enabling platform removal of any homodimeric species
(Fig. 7A). Previous to our work, asymmetric Protein A-binding
strategies for Hc homodimer removal have not been used in
combinationwith aCH3HD technology but have been success-
fully used by other groups as stand-alone techniques (15, 32,
33). However, without CH3 HD technology, bsAb recovery is
poor (50% of bispecific content at harvest). Finally, to address
the Lc pairing issue inherent to Hc heterodimers, we used the
scFv Fab format. Aside from developing a common Lc, using
this format is one of the most straightforward ways not only to
bypass Lcmispairing but also to avoid additional side products,
aswell as enabling a rapid reformatting of twodifferent parental
antibodies in a bsAb. In our view, technologies that steer Lc
pairing may not be sufficient to completely prevent mispairing
(10, 16) and thus may require additional downstream purifica-
tion steps when scaled up. One key benefit of the scFv  Fab
format is its unique molecular weight signature that facilitates
analytical analysis.
Proof-of-concept BEAT antibodies were designed to co-tar-
get different pairs of validated tumor antigens (EGFR/HER3
and HER2/HER3). HD rates in the scFv  Fab format were
lower than the levels observedwith themonovalent dAb format
Figure 8. Biochemical characterization of BEAT 2/3. A, thermal stability by DSC. An overlay of the BEAT 2/3 without (solid line) and with the D84.4Q
substitution (dashed line) is shown. The first transition corresponds to the melting of the scFv moiety and the BEAT Fc region (69.5 °C), and the second
transition accounts for the melting of the Fab portion (81.5 °C). B, size-exclusion chromatography profiles of BEAT 2/3 and its D84.4Q variant: top, BEAT 2/3
(94% monomer); bottom, BEAT 2/3 variant with the D84.4Q substitution (92% monomer). C and D, co-binding of BEAT 2/3 to recombinant HER2 and HER3
extracellular domains monitored by SPR; the length of each antigen injection is indicated by a double-headed arrow.
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discussed earlier and usually reached 70–75% in transient
transfections (Fig. 7, B and C); optimizing chain ratios, adding
the Q3A substitution in chain (A) or different substitutions at
position 90 in chain (B), helped to achieve levels of75%. Ret-
rospectively to our structural study and the making of our
proof-of-concept bsAbs, we identified the D84.4Q substitution
thatwas found to greatly improveHD in this format,most likely
by disfavoring the formation of (B) chain homodimers. Adding
the D84.4Q substitution to the original BEAT interface allowed
HD levels to routinely reach between 85 and 95% at a 1:1:1
chain ratio (Fig. 7, D and E). The variability observed for the
original BEAT interface and to a lesser extent for the BEAT
D84.4Q interface also correlatedwith the nature of the parental
antibodies and their expression levels and how well these anti-
bodies converted into the scFv format; however, stably trans-
fected CHO clones using the original interface consistently
showed HD levels with a median of distribution of 80% with
some clones reaching levels of 90–95% (34). The combina-
tion of good HD and platform removal of homodimer traces
give robustness to our technology as it enables a clone selection
based on a range of good properties (yield, stability, and glyco-
sylation profile) rather than selecting purely on HD rate.
BEAT antibodies had IgG1-like affinities for Fc receptors
(supplemental Table S1), good affinities for their target anti-
gens (supplemental Table S3), good biophysical properties (Fig.
8), and benefited from a prolonged serum half-life in rodents
(supplemental Table S2). The bsAbs exhibited superior in
vitro efficacy over another anti-EGFR/HER3 bsAb bench-
mark (two-in-one antibody technology) (Fig. 9, A–C) (29).
Importantly, our anti-HER2/HER3 BEAT antibody showed
comparable efficacy to the two-in-one antibody in a Calu-3
xenograft model (Fig. 9D and supplemental Table S4),
Figure 9. In vitro and in vivo efficacy of BEAT antibodies. A–C, BEAT 1/3 and 2/3 inhibited tumor growth in vitro more potently compared with the
monotherapies and their combinations. BxPC3 (A) and Calu-3 (B and C) cells were treatedwith antibodies or a combination of antibodies in a dose-dependent
manner in thepresence of heregulin. Cell proliferationwas assessed after 72 hof treatment usingAlamar Blue. Data are shownasmean S.E. plotted fromone
representative experiment. D, BEAT 2/3 inhibited tumor growth in vivo more potently compared with the monotherapies. Mice were treated every 3–4 days
from day 12; tumor growth was monitored until day 40. Monotherapies and bispecific antibodies were dosed at 15 mg/kg; for combination therapies, each
antibody was injected at 7.5 mg/kg. Data are presented as the tumor size (cm3) of each mouse at day 40 after xenograft; for each group, the mean S.E. is
shown. Control (CTRL) indicates treatment with PBS. Asterisks denote statistically significant p values.
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thereby validating our bispecific format for the design of
future therapeutic bsAbs.
In summary, we have shown that interfaces between Ig con-
stant domain pairs can be exchanged to design new het-
erodimers and that combining interface exchange, asymmetric
Protein A binding, and the scFv Fab format enabled the rapid
reformatting and scale-up of any antibody pair into a bsAb.
Experimental procedures
Molecular biology
cDNA coding sequences of engineered CH3 and CH4
domainswere designed in silicoprior to being gene-synthesized
at GENEART AG (Regensburg, Germany). The engineered Fc-
like proteins based onCH4orCH3domainswere engineered as
follows: a first chain comprising a human IgG1 hinge, an IgG1
CH2 domain, and a first engineered CH3 or CH4 domain; and a
second chain comprising a human VL domain, an IgG1 hinge,
an IgG1 CH2 domain, and a second engineered CH3 or CH4
domain. Protein A binding in CH4 domains was engineered via
the R115H and V116Y substitutions (IMGT numbering). PCR
products were cloned into a modified pcDNA3.1 plasmid
(Invitrogen AG, Basel, Switzerland) carrying oriP, which is the
origin of plasmid replication of Epstein-Barr virus. For asym-
metric Protein A binding, BEAT antibodies were engineered
with a BEAT CH3 (A) domain originating from human IgG3;
the BEAT 2/3 antibody used in the rat pharmacokinetic study
was engineered with both CH2 and CH3 domains originating
from human IgG3 in its BEAT Fc chain (A).
Transient expression and purification
Recombinant Fc-like proteinswere produced by co-transfec-
tion of a first engineered Fc-like chain and a second VL-Fc-like
chain. BEAT antibodies were expressed by co-transfecting a
first scFv-Fc-like heavy chain (scFv arm), a second engineered
heavy chain (Fab arm), and the cognate light chain to the Fab
arm heavy chain. Equal quantities of each engineered chain
vector were co-transfected into suspension-adapted HEK293-
EBNA cells (catalog no. ATCC-CRL-10852, LGC Standards,
Teddington, UK) using polyethyleneimine. Cells were cultured
for a period of 4–5 days before harvest. Cell-free culture super-
natants were prepared by centrifugation followed by filtration.
Fc-like proteins were purified by Protein A chromatography
operated under gravity flow (CaptivA Protein A resin, Repli-
gen, Waltham, MA) before SDS-PAGE analysis (4–12% acryl-
amide). For BEAT antibodies, aliquots of cell-free supernatants
were first purified by Protein G chromatography operated
under gravity flow (Sepharose 4 Fast Flow; GE Healthcare
Europe GmbH, Glattbrugg, Switzerland) to assess het-
erodimer content by SDS-PAGE before differential Protein
A chromatography.
Heterodimerization assay of Fc-like proteins
The proportions of heterodimer to homodimers in the Pro-
teinA-purified preparationswere determined by scanning den-
sitometry analysis of the non-reduced SDS-polyacrylamide gel
bands (4–12%, Coomassie staining). Traces of the VL-Fc-like
chain (half-molecule, 37.2 kDa) were found for most Fc-like
proteins; hence bands below the 49-kDa marker were
excluded frommeasurements. Relative ratios of the different
gel bands were quantified using a FluorChem SP imaging
system (Witec AG, Littau, Switzerland) following the man-
ufacturer’s protocol.
BEAT Fc preparation, crystallization, and structure
determination
DNA constructs for crystallization were prepared as follows.
A cDNA coding the engineered CH3 domain of BEAT (A)
(IgG3 isotype) and the engineered CH3 domain of BEAT (B)
(IgG1 isotype) were synthesized. Using PCR assembly tech-
niques, each chain had their respective engineered CH3
domain cDNA coding sequence fused downstream of a human
IgG1 hinge (DKTHTCPPCP) and an IgG1 CH2 constant
domain sequence (separately synthesized). A polyhistidine
sequence was fused at the C terminus of the BEAT (A) chain
(BEAT (A) His chain). Finally, the BEAT (A) His chain and
BEAT (B) chain coding DNA sequences were ligated into inde-
pendent vectors and co-expressed in HEK293-EBNA cells as
described above. To ensure complete removal of homodimer
contaminants (which were not identifiable by SDS-PAGE due
to the almost identical molecular weights of both chains), the
BEAT Fc was purified in a two-step procedure. In a first step,
the filtered cell culture supernatant was applied to a Protein
A-Sepharose column (GE Healthcare Europe GmbH). Because
the BEAT (A) CH3 domain was of the IgG3 isotype, no poten-
tial BEAT (A) His chain homodimers bound Protein A. After
loading, the column was washed with phosphate buffer (20 mM
Na2HPO4, pH 8, 0.15–1 M NaCl). Elution was achieved with
0.1 M glycine, pH 3, followed by immediate neutralization of the
sample with 10% v/v of 1 M Tris-HCl, pH 8. Eluted fractions
were further purified in a second step via Ni2-nitrilotriacetic
acid resin (Qiagen GmbH, Hombrechtikon, Switzerland)
according to the manufacturer’s protocol, a step that elimi-
nated any potential BEAT (B) homodimers as these donot carry
a polyhistidine tag sequence. The purified BEAT Fc was dia-
lyzed against PBS, pH 7.4. Crystallization trials and structure
determination were performed at Crelux GmbH (Martinsried,
Germany). In brief, crystals of BEAT Fc were obtained using
hanging drop vapor diffusion setups after reductive methyla-
tion of the protein (Hampton Research Reductive Alkylation
Kit, catalog no. HR2-434, Hampton Research, Aliso Viejo, CA).
0.8 l of BEAT Fc solution (10.2 mg/ml in 10 mM Tris-HCl, 0.1
M NaCl, 1 mM EDTA, pH 8) was mixed with 0.8 l of reservoir
solution (27% (w/v) PEG1500) and equilibrated at 20 °Cover 0.2
ml of reservoir solution. Well diffracting crystals appeared
within 1 day and grew over 3–4 days to full size. A complete
data set of a BEAT Fc crystal was collected at the Diamond
Synchrotron Radiation Source, Beamline i04, Didcot, UK.
Molecular replacement was performed using one chain of a
published human IgG1 Fc structure (PDB accession code
1H3T) as a search model (35). Several rounds of alternating
manual rebuilding and refinement with REFMAC5 (36)
resulted in the final model. Data deposition: the atomic coordi-
nates of the BEAT Fc structure have been deposited with the
Protein Data Bank under code 5M3V.
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Antibodymodeling
Homologymodelingwas performed using the YASARA soft-
ware (37). Interdomain interactions were analyzed using the
on-line PIC server (http://pic.mbu.iisc.ernet.in/)5 (38). The
interdomain interactions for IgG1 CH3 were calculated from
PDB code 1H3T. Interactions in TCR Ca-Cb were analyzed
from PDB codes 1KGC and 2CDF. Interactions in TCR Cg-Cd
were analyzed from PDB code 1HXM. The BEAT CH3 het-
erodimer was firstmodeled fromPDB code 1H3T, and interdo-
main interactions were analyzed for engineering; upon struc-
ture determination of the BEAT Fc, interdomain interactions
were analyzed and reported herein. A homology model for
BEAT min was calculated based on the solved structure of the
BEAT Fc. For BEAT G/D, a homology model was built based on
PDB code 1H3T, and the interdomain interactions were ana-
lyzed. As there is no solved crystal structure available for IgM, a
homology model of IgM CH4 was built based on IgG1 CH3
(PDB code 1H3T). A homology model for BEATCH4 was then
built based on the homology model of IgM CH4. Homology
models for MI heterodimers were built based on IgG1 CH3
(PDB code 1H3T). Interdomain interactions in IgA CH3 were
calculated from PDB code 1OW0. A homology model of the
SEED body CH3 heterodimer was built based on PDB code
1H3T. As there is no solved crystal structure available for IgD, a
homology model for IgD CH3 was built based on PDB code
1H3T.
Differential Protein A chromatography of BEAT antibodies
Cell-free supernatants were loaded onto a 1-ml HiTrapTM
MabSelect SuReTM Protein A column pre-equilibrated in 0.2 M
citrate/phosphate buffer, pH 6, and operated on an ÄKTATM
purifier chromatography system (both from GE Healthcare
Europe GmbH) at a flow rate of 1 ml/min. Running buffer was
0.2 M citrate/phosphate buffer, pH 6. Wash buffer was 0.2 M
citrate/phosphate buffer, pH 5. Heterodimer elution was per-
formed using 20 mM sodium acetate buffer, pH 4.1, although
homodimeric species were unbound (IgG-like homodimers) or
eluted with 0.1 M glycine, pH 3 (scFv-Fc homodimers). Elution
was followed by absorbance reading at 280 nm; relevant frac-
tions were pooled and neutralized with 0.1 volume of 1 M Tris-
HCl, pH 8. Fractions were analyzed under non-reduced condi-
tions by SDS-PAGE.
SPR analysis of BEAT antibodies
Experiments were performed on a Biacore 2000 or Biacore
T200 instrument (GEHealthcare Europe GmbH) at room tem-
perature. Data fitting was performed using the BIAevaluation
software version 4.1 or the Biacore T200 Evaluation Software
version 3.0 (both from GE Healthcare Europe GmbH).
Binding affinities for EGFR, HER2, and HER3 extracellular
domains
Protein A (Thermo Fisher Scientific, LuBioScience GmbH,
Lucerne, Switzerland) or Protein G (Thermo Fisher Scientific)
were coupled to a CM5 sensor chip (GE Healthcare Europe
GmbH) using an amine coupling kit (GE Healthcare Europe
GmbH). Before each antigen injection, BEAT antibodies were
captured to reach about 200 response units. EGFR, HER3, and
HER2 (extracellular domains produced in-house as polyhisti-
dine-tagged proteins) were injected at 3–100 nM. Regeneration
was performed with 0.1 M glycine, pH 1.5. Data fitting was per-
formed using the 1:1 Langmuir binding model.
Antigen co-binding experiments
BEAT antibodies were captured on a Protein G-coupled
CM5 sensor chip to reach200 response units. After response
stabilization, relevant antigens (EGFR, HER2, or HER3) were
sequentially injected at 200 nM for 4 min.
Binding affinities for human Fc receptors
Human Fc receptor extracellular domains were cloned,
expressed, and purified in-house. KD values for FcR2a (Uni-
Prot P12318, variant H167), FcR2b (UniProt P31994), FcR3a
(UniProt P08637, variant V176), and FcRn (UniProt P55899
and P61769) were measured via direct covalent coupling of the
antibody onto a CM5 sensor chip. Dissociation was monitored
for 2 min (FcR2a, FcR2b, and FcRn) or 12 min (FcR3a). No
regeneration step was needed for FcR2a, FcR2b, and FcR3a
as complete dissociation was observed. For FcRn measure-
ments, regeneration was performed by injecting 2  10 l of
HBS-EP, pH 7.4 (GE Healthcare Europe GmbH). All data
were processed using the steady-state fitting model. HBS-EP
buffer was used as running buffer; for FcRn measurements,
HBS-EP buffer was adjusted to pH 6. Affinities for FcR1a
(UniProt P12314) weremeasured via Protein A capture. Exper-
imental data for FcR1a were processed using a 1:1 Langmuir
model with the Rmax value set to local in all fits. After each
binding event, the surface was regenerated with 10 mM glycine
buffer, pH 1.5.
Differential scanning calorimetry
Measurements were carried out on aMicroCal VP-Capillary
differential scanning calorimeter (Malvern Instruments Ltd.,
Malvern, UK). The cell volume was 0.128 ml, the heating rate
was 1 °C/min, and the excess pressure was kept at 64 p.s.i. All
protein samples were tested at a concentration of 1–0.5 mg/ml
in PBS, pH 7.4. The partial molar heat capacities and melting
curves were analyzed using standard procedures. Thermo-
gramswere baseline-corrected, and concentrationwas normal-
ized before being further analyzed using a non-two-statemodel
in the software Origin version 7.0 (supplied byMalvern Instru-
ments Ltd).
Size-exclusion chromatography
Analytical SEC was performed using a Tosoh Bioscience
TSKgel G3000SWxl column (catalog no. 08541, Tosoh Biosci-
ence AG, Lucerne, Switzerland) at room temperature with 0.1
M sodium phosphate buffer, 0.15 M sodium chloride, pH 6.8, as
eluent at 1 ml/min flow rate, on a Waters Alliance 2695 HPLC
system with a Waters 2998 PDA detector (Waters AG, Baden-
Dättwil, Switzerland), monitoring at 214 and 280 nm.
PK study
Pharmacokinetics analyses were conducted in female
Sprague-Dawley rats. Each group contained four rats. Rats
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received 10 mg/kg BEAT 2/3 by intravenous bolus injection.
Blood samples were collected at 0.25, 1, and 6 h and at 1, 2, 4, 5,
7, 10, 14, 21, 28, and 42 days post-injection. Serum levels of
BEAT 2/3 were determined by sandwich ELISA. HER2 antigen
(extracellular portion of HER2 fused to a human Fc and pro-
duced in-house) was coated onto 96-well ELISA plates at a con-
centration of 2g/ml and incubated overnight at 4 °C. After the
plates were blocked with BSA, serum samples, reference stan-
dards (11 serial dilutions), and quality control samples were
added to the plate and incubated for 1 h at room temperature.
After washing to remove unbound antibody, peroxidase-conju-
gated goat anti-human IgG_F(ab)2 fragment-specific detec-
tion antibody (Jackson ImmunoResearch, distributor: MILAN
ANALYTICA AG, Rheinfelden, Switzerland, catalog no. 109-
035-006) was added and developed by standard colorimetric
tetramethylbenzidine substrate (Pierce-Thermo Fisher Scien-
tific-Perbio Science S.A., Lausanne, Switzerland) according to
the manufacturer’s recommendations. Absorbance values at
450 nmwere recorded on a plate reader, and the concentrations
of antibody in serum samples were calculated using the refer-
ence standard curve generated in the sample plate utilizing four
parametric regression models. The pharmacokinetics parame-
ters were evaluated by non-compartment analysis using
WinNonlinTM version 5.3 (PharsightCorp.,MountainView,CA).
Reference antibodies
Analogue antibodieswere cloned and expressed according to
previously published variable domain sequences as follows:
Herceptin (21), Erbitux (20), anti-HER3 (22), and duligotu-
zumab (39).
Cancer cell lines
Calu-3 (catalog no. ATCC-HTB-55) and BxPC3 (catalog no.
ATCC-CRL-1687) cell lines were purchased from American
Type Cell Culture (ATCC-LGL standards, Teddington, UK).
Calu-3 and BxPC3 cells were maintained in RPMI 1640
medium supplemented with 10% fetal calf serum (FCS) and 1%
GlutaMAX/penicillin/streptomycin.
Cell proliferation assays
Calu-3 (10,000 cells/well) and BxPC3 (8000 cells/well) cells
were seeded in 96-well plates. The following day, cells were
treated with antibodies or combinations of antibodies diluted
in medium containing 1% FCS. For combination treatments,
equal concentrations of antibodies were mixed to reach a total
antibody concentration that was equal to the comparable single
treatment. 3 nM heregulin (R&D Systems, Abingdon, UK, cata-
log no. 396-HB)was added after 1 h of incubationwith antibod-
ies or combinations. Alamar Blue (AbD Serotec, Düsseldorf,
Germany) was added to the wells after 72 h, and the cells were
incubated up to 24 h, before fluorescence was read on a Biotek
Synergy 2 plate reader (BioTek Instruments GmbH, Luzerne,
Switzerland) at an excitation wavelength of 540 nm and an
emission wavelength of 620 nm.
Xenograft studies
Xenograft studies were performed at Accelera Srl (Nerviano,
Milano, Italy). In vivo experiments were performed in female
5-week-old naive SCID beigemice (Charles River Laboratories,
Calco, Lecco, Italy). All experimentswere done according to the
Italian Animal Protection Lawwith authorization from the vet-
erinary authorities. Calu-3 cells were injected subcutaneously
(5  106 cells) in the right flank of female naive SCID beige
mice. When tumors had reached a volume of 100 to 300 mm3,
mice were randomized and assigned to treatment groups, with
a target of 10 mice per group. When treatment started, the
mean tumor volume was 190 mm3 on day 12, and subse-
quently tumor growth was monitored every 3–4 days until day
40. Multiple-dose studies consisted of 5 weeks of treatment
with the first dose on the day of randomization (intraperitoneal
injections on day 15, 19, 22, 26, 29, 33, and 36). Tumor growth
was determined by external caliper measurements, and tumor
volumes were calculated using a standard hemi-ellipsoid for-
mula (tumor volume (mm3)	 0.5 length (width)2).Mono-
therapies and bispecific antibodies were dosed at 15 mg/kg; for
combination therapies, each antibody was injected at 7.5
mg/kg. For all in vivo results, data were analyzed using the
Graphpad Prism 5 software (GraphPad Software Inc., La Jolla,
CA). Data were analyzed for statistical significance using the
one-way analysis of variance followed by a Dunnett’s post hoc
test for multiple comparisons or the Mann Whitney test for
pairwise comparisons. p values of less than 0.05 were regarded
as statistically significant.
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